How to Get Trulicity in Maryland: Prescriptions, Telehealth, and Pharmacy Access

What Is Trulicity and Why Maryland Patients Request It

Trulicity is the brand name for dulaglutide, a once-weekly injectable GLP-1 receptor agonist approved by the FDA in September 2014 for glycemic control in type 2 diabetes. The FDA expanded its label in 2020 to include cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [1]

Dulaglutide mimics the incretin hormone GLP-1. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. [2] Because it is injected only once per week, adherence rates in clinical practice are generally higher than with daily injectables.

The REWIND trial (N=9,901) followed patients for a median of 5.4 years and found that dulaglutide 1.5 mg once weekly reduced the composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death by 12% compared with placebo (HR 0.88 to 95% CI 0.79 to 0.99, P<0.026). [3] That cardiovascular outcome label is a key reason Maryland cardiologists and endocrinologists now co-prescribe dulaglutide alongside statins and antihypertensives.

Mean HbA1c reduction in REWIND was 0.61 percentage points from a baseline of 7.3%. [3] Separate dose-escalation data from AWARD-11 (N=1,842) showed that 4.5 mg dulaglutide produced a mean HbA1c reduction of 1.77% and a body-weight reduction of 4.7 kg at 36 weeks versus 1.54% and 2.7 kg for the 1.5 mg dose. [4]

Who Can Prescribe Trulicity in Maryland

Any Maryland-licensed prescriber with DEA registration and the authority to prescribe Schedule III-V and non-scheduled drugs may write a Trulicity prescription. That group includes MDs, DOs, nurse practitioners (NPs) with prescriptive authority under the Maryland Board of Nursing, and physician assistants (PAs) under delegated authority from a supervising physician.

Maryland NPs practice under full prescriptive authority after completing the Board of Nursing's attestation process. [5] PAs may prescribe under a written delegation agreement that does not require co-signature for non-controlled substances, meaning a PA at a telehealth practice can issue a dulaglutide Rx without the supervising MD reviewing each chart before transmission. [6]

Endocrinologists, primary-care physicians, and cardiologists are the most common prescribers. Given the expanded cardiovascular indication, internists managing patients with known coronary artery disease or peripheral arterial disease increasingly initiate dulaglutide as first-line injectable therapy, consistent with the 2023 American Diabetes Association Standards of Care, which recommend GLP-1 receptor agonists for patients with type 2 diabetes and atherosclerotic cardiovascular disease regardless of baseline HbA1c. [7]

Telehealth Prescribing for Trulicity in Maryland

Maryland permits telehealth prescribing of non-controlled substances including dulaglutide under Maryland Health-General §19-141 and the Maryland Board of Physicians' telehealth guidelines. [8] A valid prescriber-patient relationship can be established through a synchronous audio-video visit. Asynchronous (store-and-forward) prescribing alone does not satisfy Maryland's standard-of-care requirement for a new patient receiving a GLP-1 injectable.

Telehealth providers licensed in Maryland may prescribe dulaglutide to Maryland residents as long as:

• The prescriber holds an active Maryland license in their respective discipline.
• A live video visit occurs (audio-only is technically permitted but suboptimal for a new injectable initiation).
• The patient's identity is verified at the start of the encounter.
• Lab values, current medication list, and contraindications are reviewed during the visit.

A typical telehealth visit for a new dulaglutide prescription runs 20 to 30 minutes. The clinician reviews HbA1c, kidney function (eGFR), a personal and family history of medullary thyroid carcinoma (MTC) or MEN2, and current medications for interactions. After the visit, the prescription is transmitted electronically to the patient's preferred Maryland pharmacy or a mail-order pharmacy licensed in Maryland. [9]

The HealthRX clinical team uses a four-checkpoint telehealth intake framework for dulaglutide candidates in Maryland:

1. Confirm diagnosis of type 2 diabetes or cardiovascular risk-reduction indication (HbA1c or physician records required).
2. Screen for absolute contraindications: personal or family history of MTC, MEN2 syndrome, prior serious hypersensitivity to dulaglutide.
3. Confirm baseline labs within 90 days: HbA1c, CMP (eGFR, hepatic panel), CBC, and fasting lipid panel.
4. Document current antidiabetic regimen and assess hypoglycemia risk before co-prescribing with sulfonylureas or insulin.

What Labs Are Required Before Starting Trulicity in Maryland

No Maryland law mandates a specific laboratory panel before initiating dulaglutide, but the FDA prescribing label and ADA guidelines define a clinical minimum. [7, 10] Most Maryland telehealth and in-person providers require these results within 90 days of the initial prescription:

HbA1c. Confirms the type 2 diabetes diagnosis (HbA1c <6.5% generally does not support a diabetes indication) and establishes a baseline for response monitoring. [7]

Comprehensive Metabolic Panel (CMP). Serum creatinine and calculated eGFR are needed because dulaglutide has been associated with acute kidney injury in post-marketing surveillance, most often secondary to nausea-induced volume depletion. Hepatic enzymes are reviewed to rule out severe hepatic impairment. No dose adjustment is needed for mild-to-moderate renal impairment, but clinical caution is warranted. [10]

Fasting Lipid Panel. The 2023 ADA Standards of Care recommend lipid monitoring at initiation of new antidiabetic therapy, particularly in patients with cardiovascular risk. [7]

TSH. Thyroid-stimulating hormone testing is not required by the FDA label but is ordered by many Maryland endocrinologists and telehealth clinicians to rule out pre-existing thyroid pathology before initiating a drug that carries a boxed warning about thyroid C-cell tumors in rodents. [10]

Urine Albumin-to-Creatinine Ratio (UACR). Recommended by the ADA for all patients with type 2 diabetes at initiation of a new injectable agent. [7]

Results can be obtained through a Maryland LabCorp or Quest draw site. Many telehealth platforms provide a standing lab order patients complete before the video visit, so the clinician reviews results live during the appointment.

Maryland Medicaid and Insurance Coverage for Trulicity

Maryland Medicaid covers dulaglutide (Trulicity) for type 2 diabetes with prior authorization (PA). The Maryland Medicaid Preferred Drug List places Trulicity in a preferred tier among GLP-1 receptor agonists, though formulary placement can shift at each annual review. [11]

Prior authorization for Maryland Medicaid typically requires:

• A confirmed diagnosis of type 2 diabetes (ICD-10: E11.x).
• Documentation of inadequate glycemic control on at least one first-line oral agent (usually metformin) unless metformin is contraindicated or not tolerated.
• A recent HbA1c (within 90 days) showing the patient is above goal, typically above 7.0% or above the individualized target set by the treating clinician.
• Prescriber attestation that the patient received diabetes education or has a referral pending.

The American Diabetes Association notes that "access to GLP-1 receptor agonists remains inconsistent across state Medicaid programs," and Maryland's PA pathway, while adding a step, does not limit coverage when criteria are met. [7]

Commercial payers operating in Maryland, including CareFirst BlueCross BlueShield, United Healthcare, and Aetna, generally cover Trulicity at the tier-3 specialty level. With a manufacturer coupon from Eli Lilly, eligible commercially insured patients may pay as little as $0 to $25 per month. Patients without insurance can access the Lilly Insulin Value Program or the Trulicity Savings Card directly through Eli Lilly's patient assistance infrastructure. [12]

How to Get Trulicity Through a Maryland Pharmacy

After a prescription is issued, four dispensing pathways are available to Maryland patients:

Retail pharmacy. CVS, Walgreens, Rite Aid, and most independent Maryland pharmacies stock Trulicity pens in 0.75 mg/0.5 mL and 1.5 mg/0.5 mL single-dose pens. Higher doses (3.0 mg and 4.5 mg) are less consistently stocked and may require a 24-to-48-hour special order. [10]

Mail-order pharmacy. Most Maryland commercial plans include a 90-day mail-order benefit. Express Scripts, CVS Caremark, and OptumRx all ship Trulicity to Maryland addresses in temperature-controlled packaging. Dulaglutide must remain refrigerated at 36°F to 46°F (2°C to 8°C). [10]

Specialty pharmacy. Some Maryland plans require specialty pharmacy dispensing for GLP-1 injectables. Accredo and Walgreens Specialty Pharmacy are common in-network options for Maryland residents.

503A compounding pharmacy. A Maryland-licensed 503A compounding pharmacy may compound dulaglutide for an individual patient when a licensed prescriber writes a prescription specifying a non-commercially available dose, formulation, or delivery method. 503A pharmacies compound for individual prescriptions and are regulated by the Maryland Board of Pharmacy under the federal Drug Quality and Security Act. [13, 14] Compounded dulaglutide is not FDA-approved and may not be bioequivalent to the branded product; patients considering this route should discuss the tradeoffs with their prescriber.

How Long Does It Take to Receive Trulicity in Maryland?

From first telehealth appointment to first injection, the typical timeline breaks down as follows:

• Day 0 to 1: Telehealth visit completed; Rx transmitted electronically.
• Day 1 to 3: PA submitted by prescriber (if required by payer).
• Day 3 to 7: PA decision returned (Maryland Medicaid target turnaround is 72 business hours for non-urgent PA).
• Day 5 to 10: Pharmacy dispenses; retail pickup same day or mail delivery in 2 to 5 business days.

Patients with commercial insurance and no PA requirement can sometimes pick up Trulicity from a retail Maryland pharmacy within hours of the appointment if stock is available. Medicaid patients navigating PA can expect 7 to 14 days in most cases. [15]

Transferring a Trulicity Prescription to Maryland

Patients relocating to Maryland from another state can transfer an existing Trulicity prescription under these conditions:

A prescription for a non-controlled substance may be transferred between pharmacies regardless of state lines, provided the original prescription has remaining refills and has not expired. Maryland does not restrict transfer of non-scheduled drug prescriptions. [16]

However, if the original prescription was written by an out-of-state prescriber who is not licensed in Maryland, that prescription remains valid for filling in Maryland at a pharmacy. The out-of-state prescriber does not need a Maryland license simply because their prescription is filled in a Maryland pharmacy. What changes is ongoing care: if the patient wants continued telehealth follow-up, the prescriber must hold a Maryland telehealth license to conduct visits with a Maryland-based patient after the patient establishes residency.

Patients who transfer to Maryland and need a new prescriber should bring their most recent lab results, current dose, and any prior authorization approval letters to the first appointment. This reduces the baseline workup to a clinical review rather than a full de novo evaluation.

Dosing and Escalation Schedule for Maryland Patients

The FDA-approved starting dose of dulaglutide is 0.75 mg subcutaneously once weekly for at least four weeks, after which the dose may be increased to 1.5 mg once weekly. [10] The AWARD-11 trial established that further escalation to 3.0 mg and then 4.5 mg at 4-week intervals produced additional HbA1c and weight reductions in patients not at goal on 1.5 mg. [4]

Injection day flexibility is a practical advantage. Patients may inject on any day of the week. If a dose is missed, it may be administered up to three days (72 hours) before the next scheduled dose. [10]

Common early side effects include nausea (reported by approximately 20% of patients in AWARD trials), diarrhea, vomiting, and decreased appetite. [4] These effects are typically dose-dependent and transient, most prominent during the first four to eight weeks of therapy. Preemptive counseling on small meal sizes and slow eating helps most Maryland patients remain adherent through the early titration phase.

What Prior Authorization Requires in Maryland

Prior authorization is required by Maryland Medicaid and by many commercial plans. The documentation package typically includes:

Clinical notes. The office or telehealth visit note documenting the type 2 diabetes diagnosis, current medications, HbA1c, and the rationale for initiating a GLP-1 agonist.

Lab results. A recent HbA1c (within 60 to 90 days) and a CMP. Some payers also request a fasting lipid panel.

Step therapy attestation. Evidence that the patient has tried and failed, or has a contraindication to, metformin at a therapeutic dose. Maryland commercial payers vary on whether step therapy with a second oral agent (e.g., SGLT2 inhibitor) is required before approving a GLP-1 injectable.

Prescriber information. NPI number, practice address, and DEA number.

Under Maryland Insurance Code §15-10B-05, insurers must respond to a non-urgent prior authorization request within 72 hours of receiving a complete submission. Urgent requests require a decision within 24 hours. [15] If a PA is denied, the prescriber may submit a peer-to-peer review request or file a formal appeal within 30 days of the denial notice.

The 2023 ADA position statement on access states: "Delays in prior authorization decisions disproportionately affect patients with diabetes who depend on time-sensitive medication adjustments." [7] Many Maryland telehealth platforms now employ dedicated PA coordinators who track submission status and follow up with payers within 24 hours of a non-response, shortening average approval timelines considerably.

Monitoring After Starting Trulicity in Maryland

Once dulaglutide is initiated, the ADA recommends repeating HbA1c every three months until the patient reaches their individualized target, then every six months during stable glycemic control. [7] Additional monitoring checkpoints include:

Renal function. eGFR should be rechecked at 3 months after initiation and annually thereafter, or sooner if the patient experiences significant nausea, vomiting, or dehydration. [10]

Weight and blood pressure. Monthly for the first three months, then quarterly. Dulaglutide produces modest but clinically meaningful blood-pressure reductions (mean 1 to 2 mmHg systolic in REWIND). [3]

Lipase. Routine lipase monitoring is not required, but the FDA label advises clinicians to discontinue dulaglutide and investigate if a patient reports severe abdominal pain radiating to the back, which may indicate pancreatitis. [10]

Thyroid palpation. Annual clinical thyroid exam is reasonable given the drug's boxed warning, though no thyroid tumor has been confirmed in human patients at approved doses. [10]

Telehealth follow-up for Maryland patients after initiating dulaglutide typically occurs at 4 weeks (tolerability review), 12 weeks (HbA1c recheck, dose escalation decision), and then every 3 to 6 months. Labs can be ordered through a Maryland draw site and results reviewed via a brief video or asynchronous message visit, depending on the platform's licensure and clinical protocols. [8, 9]